Cipepofol

Summary

Cipepofol (CHEMBL4094894) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including kidney disorder and depressive disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 75
• Chemistry: 204.31 Da · C14H20O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4094894
Name	Cipepofol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	86301664
Molecular formula	C14H20O
Molecular weight	204.31
InChIKey	BMEARIQHWSVDBS-SNVBAGLBSA-N

SMILES: C[C@H](C1CC1)C2=CC=CC(=C2O)C(C)C

IUPAC name: 2-[(1R)-1-cyclopropylethyl]-6-propan-2-ylphenol

Also known as: Cipepofol, Ciprofol, Hsk-3486, HSK-3486, HSK-3486, (R)-, Hsk3486, HSK3486, CIPEPOFOL

Patent coverage: 32 distinct patent families (69 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 67 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
kidney disorder	1	MONDO:0005240	EFO:0003086
depressive disorder	0	MONDO:0002050	MONDO:0002050

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 75.

Phase distribution

Phase	Trials
Not specified	22
PHASE1	17
PHASE4	16
PHASE3	11
PHASE2	5
EARLY_PHASE1	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06674226	PHASE4	RECRUITING	Effects of Ciprofol on Postoperative Delirium and Outcomes in Elderly Patients Undergoing Major Thoracic Surgery
NCT06740201	PHASE4	RECRUITING	A Study to Evaluate the Accuracy of aTCI Model of Cipepofol in Patients With General Anesthesia During Elective Surgery
NCT06773351	PHASE4	NOT_YET_RECRUITING	A Response Surface Analysis for the Interaction Between Ciprofol and Sevoflurane
NCT06934811	PHASE4	NOT_YET_RECRUITING	Ciprofol’s Impact on Oxygenator Function in Extracorporeal Membrane Oxygenation (ECMO) Patients
NCT06952608	PHASE4	RECRUITING	Effect of Ciprofol on Intraoperative Hypotension in Elderly Patients Receiving Renin-angiotensin System Inhibitors
NCT07028593	PHASE4	RECRUITING	Effects of Ciprofol on Myocardial Injury After Non-cardiac Surgery in Video-Assisted Thoracoscopic Surgery
NCT07118579	PHASE4	RECRUITING	Effects of Remimazolam and Ciprofol TIVA on PRAE in Pediatric Tonsillectomy and Adenoidectomy
NCT05035069	PHASE4	UNKNOWN	Efficacy and Safety of Ciprofol Compared to Propofol for Nonintubated General Anesthesia in Patients Undergoing TAVR
NCT05518929	PHASE4	COMPLETED	Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
NCT05522998	PHASE4	COMPLETED	Efficacy and Safety of Ciprofol in Laparoscopic Sleeve Gastrectomy
NCT05664386	PHASE4	UNKNOWN	Effect of Ciprofol Infusion for Induction and Maintenance on Hemodynamics and Postoperative Recovery
NCT05706337	PHASE4	UNKNOWN	Clinical Observation of Ciprofol for Anesthesia Induction
NCT05881291	PHASE4	COMPLETED	Efficacy and Safety of Ciprofol for General Anaesthesia in Patients Undergoing Transcatheter Aortic Valve Replacement
NCT06095570	PHASE4	UNKNOWN	The Study of Ciprofol for the Suppression of Cardiovascular Responses to Tracheal Intubation
NCT06344949	PHASE4	COMPLETED	Ciprofol Versus Propofol for Tracheal Intubation in ICU
NCT06425757	PHASE4	COMPLETED	Study on Pharmacokinetics of Single Injection of Ciprofol in Patients With Moderate to Severe Hypoproteinemia
NCT07510945	PHASE3	NOT_YET_RECRUITING	HSK3486 (Cipepofol) Injectable Emulsion for Induction of General Anesthesia in Pediatric Subjects Undergoing Elective Surgery
NCT03674008	PHASE3	COMPLETED	A Phase III Study Evaluating The Efficacy and Safety of HSK3486 for Sedation or Anesthesia
NCT03808844	PHASE3	COMPLETED	A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion for the Induction of General Anesthesia in Elective Surgery Subjects
NCT04111159	PHASE3	COMPLETED	A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Subjects Undergoing Fiberoptic Bronchoscopy
NCT04511728	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of HSK3486 in the Induction of General Anesthesia
NCT04620031	PHASE3	COMPLETED	A Study Evaluating Sedation of Intravenous Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Mechanical Ventilation
NCT04711837	PHASE3	COMPLETED	Efficacy and Safety of HSK3486 Compared to Propofol in Induction of General Anesthesia in Adults Having Elective Surgery
NCT04958746	PHASE3	COMPLETED	Phase III Clinical Trial Evaluating the Efficacy and Safety of Ciprofol Injection for the Induction of Sedation/Anesthesia in Subjects Undergoing Gynecological Outpatient Surgeries
NCT05478174	PHASE3	COMPLETED	Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia
NCT05486416	PHASE3	COMPLETED	Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery
NCT06391931	PHASE3	COMPLETED	A Multicenter, Open, Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Cipepofol Injection for General Anesthesia in Pediatric Patients Undergoing Elective Surgery
NCT03698617	PHASE2	COMPLETED	A Phase IIa Study Investigating the Tolerance, Efficacy and Safety of HSK3486
NCT03709056	PHASE2	COMPLETED	A Study Evaluating the Efficacy and Safety of HSK3486
NCT03773042	PHASE2	COMPLETED	A Study Evaluating Tolerability, Efficacy, and Safety of HSK3486 Injectable Emulsion in Patients
NCT04048811	PHASE2	COMPLETED	A Clinical Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Elective Surgery Patients
NCT04669821	PHASE2	COMPLETED	A Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 in ICU Patients Undergoing Long-Term Mechanical Ventilation
NCT03745625	PHASE1	COMPLETED	A Study Evaluating the Safety and Pharmacokinetics/Pharmacodynamics of HSK3486
NCT03751956	PHASE1	COMPLETED	A Study Evaluating the Mass Balance of [14C]HSK3486 Emulsion Injection in Healthy Adults.
NCT03751969	PHASE1	WITHDRAWN	A Study Evaluating the Mass Balance of Micro-dose[14C]HSK3486 Emulsion Injection in Healthy Adults
NCT03758469	PHASE1	COMPLETED	A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules
NCT03773835	PHASE1	COMPLETED	A Study Evaluating Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Single IV Dose of HSK3486 Injectable Emulsion in Healthy Subjects.
NCT04029766	PHASE1	COMPLETED	A Study Evaluating Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of HSK3486 Single Bolus Dose Followed With a 30 Minute Constant Infusion in Healthy Male Subjects
NCT04033939	PHASE1	COMPLETED	A Study Evaluating the Safety, Pharmacodynamics and Pharmacokinetics of HSK3486 in Healthy Subjects.
NCT04037657	PHASE1	COMPLETED	Evaluating the Safety, Pharmacodynamics and Pharmacokinetics of HSK3486 in Healthy Female Subjects.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).